Pre-implantation Genetic Testing (PGT)

The Australian Government announced $95.9 million in funding for Pre-implantation Genetic Testing (PGT) listing on the Medicare Benefits Schedule (MBS) on 9 May 2021.

Five new items will be implemented on the MBS from 1 November 2021 to support eligible Australians to access this testing.

The five new items to be listed on the MBS include an item to test the reproductive couple for pathogenic variants (73384), one surgical item for an embryo biopsy from an at risk couple as identified by the first test (13207), and a further three items for genetic testing of the biopsied embryo(s) (73385, 73386, 73387).

Eligibility for PGT items are restricted to patients and (if relevant) a reproductive partner with a recognised risk of having a child affected by a Mendelian or mitochondrial disorder, autosomal dominant disorder, or chromosome disorder, for which there is no curative treatment and there is a severe limitation of quality of life despite contemporary management.

PDF version of the Pre-implantation Genetic Testing (PDF 150 KB)

Word version of the Pre-implantation Genetic Testing (Word 94 KB)